On September 23, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will present data regarding its Rhenium-186 NanoLiposome (186RNL) investigational radiotherapeutic for recurrent glioblastoma (GBM) at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting being held in person October 24-27, 2021 in Chicago, Illinois (Press release, Cytori Therapeutics, SEP 23, 2021, View Source [SID1234590202]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the abstract and poster viewing Q&A session are as follows:

Title Image-guided Rhenium-186 NanoLiposome (186RNL) brachytherapy in the treatment
of recurrent glioblastoma: technique, image analysis, dosimetry, and monitoring
Date October 27, 2021 at 1:00 p.m. CT / 2:00 p.m. ET
Location McCormick Place West, Outside Room W375
Presenter John Floyd, M.D., University of Texas Health Science Center San Antonio, and study
investigator
The abstract and poster will be accessible online in the ASTRO conference planner on October 22, 2021 at 5:00 p.m. CT / 6:00 p.m. ET. A copy of the poster will be made available under the Presentations tab of the Investors section of the Company’s website at the time of the presentation at www.plustherapeutics.com.